IMMUNE & THYMIC / MATRIX
Two Thymic Peptides, Side by Side
Where Thymosin Alpha-1 and Thymulin converge, where they diverge, and how far the evidence behind each one actually reaches.
The short version
This page lines up Thymosin Alpha-1 and Thymulin on the dimensions that matter most when reading immune research peptides: what kind of molecule each one is, where it has been studied, how strong that evidence is, how it was administered in studies, its regulatory standing, and its single biggest caution. The headline difference is stark: Thymosin Alpha-1 is an internationally approved drug (thymalfasin) with four decades of human clinical data, while Thymulin has no approved human indication anywhere and is based mainly on preclinical models. They both originate from the thymus and both modulate T-cell function — but they are structurally unrelated, mechanistically distinct, and at very different stages of clinical development. Neither is presented here with a human dose.
The comparison matrix
| Dimension | Thymosin Alpha-1 | Thymulin |
|---|---|---|
| Peptide class | 28-amino-acid N-terminally acetylated thymic polypeptide | Zinc-dependent thymic nonapeptide hormone (9 aa) |
| Most-studied in | Chronic viral hepatitis, sepsis, cancer immunotherapy | T-lymphocyte differentiation, asthma (gene-therapy model), CNS anti-inflammation |
| Evidence base (model) | Four decades of human RCTs; approved in 35+ countries [2] | Mostly rodent and cell models; gene-therapy vectors; no human trials [9][11] |
| Administration studied | Subcutaneous (clinical); IV safety pilot; multiple-dose regimens [2] | Adenoviral/plasmid gene delivery in animals; intratracheal nanoparticles in mice [8][9] |
| Regulatory status | Approved as thymalfasin in 35+ countries; not FDA-approved for US marketing [2] | Not approved anywhere; research chemical only [11] |
| Key caution | Largest sepsis RCT (1,106 adults) was null; efficacy expectations must be tempered [1] | Activity is strictly zinc-dependent; gene-therapy delivery gap limits translation [12] |
Peptide class
The two peptides share a thymic origin but are structurally unrelated. Thymosin Alpha-1 is a 28-amino-acid polypeptide with an N-terminal acetyl group that is essential for activity — remove it, and the molecule loses its biological function [7]. Thymulin is nine amino acids long, making it roughly one-third the size, and its defining feature is a strict zinc requirement: the zinc-bound form (Zn-thymulin) is biologically active; the apo (zinc-free) form is not [12]. This zinc-gate has no parallel in Thymosin Alpha-1's biology.
Most-studied in
Each peptide has a distinct research territory. Thymosin Alpha-1's evidence base is concentrated in three clinical contexts: chronic viral hepatitis (the strongest and most consistent signal), sepsis (a mixed and now-disputed story ending in a null phase-3 RCT), and cancer immunotherapy as an adjuvant to checkpoint inhibitors and chemotherapy [2][4]. Thymulin's research territory is primarily preclinical: T-lymphocyte differentiation models, anti-inflammatory studies in LPS-challenged mice [10], and gene-therapy models of allergic asthma [8] and thymodeficiency-associated neuroendocrine abnormalities [9].
Evidence base (model)
This is the sharpest separation between the two. Thymosin Alpha-1 has more human clinical data than almost any other research-context peptide: phase-3 double-blind RCTs, a comprehensive four-decade safety review, international approvals, and a large post-marketing dataset [1][2]. That track record does not mean all outcomes are positive — the 2025 TESTS trial (1,106 adults) found no sepsis mortality benefit [1] — but it means the safety profile and pharmacokinetics are genuinely characterized in humans. Thymulin's evidence base, by contrast, is almost entirely preclinical: rodent models and cell cultures, with the most dramatic results from gene-therapy delivery vectors rather than direct peptide administration [8][9]. No published human clinical trials of thymulin exist [11].
Administration studied
Routes reflect the research maturity of each compound. Thymosin Alpha-1 is routinely given subcutaneously in clinical settings (0.8–6.4 mg per dose), with intravenous routes explored in pilot work [2]. Thymulin's route in the most compelling efficacy studies is gene-therapy delivery — plasmids in mucus-penetrating nanoparticles given intratracheally [8] or adenoviral vectors [9] — rather than direct peptide injection. This delivery gap is one of the reasons thymulin's clinical translation remains unresolved [11].
Regulatory / WADA status
The contrast in regulatory status is the clearest dimension on this table. Thymosin Alpha-1 (thymalfasin) is approved as a prescription drug in more than 35 countries for hepatitis B and C and related immune indications [2]; it is not FDA-approved for US marketing, but internationally it is a regulated pharmaceutical. Thymulin has no approved indication anywhere and is classified as a research chemical [11]. Neither is specifically prohibited by WADA by name, but both fall in categories (immunomodulatory peptides, thymic peptides) that warrant caution in competitive sport contexts.
Key caution
Each peptide carries a defining caveat that any careful reader should hold onto. For Thymosin Alpha-1, the key caution is the 2025 TESTS trial: the largest, most rigorous RCT ever run for this peptide in sepsis found no significant mortality benefit (HR 0.99, P=0.93), directly tempering earlier positive but smaller studies [1]. For Thymulin, the key caution is structural: its biological activity requires zinc binding, its best evidence comes from gene-therapy delivery models rather than direct peptide use, and human pharmacokinetics are not established [12][9]. Together, the lesson is precise: one peptide has human safety data and a mixed efficacy record; the other has interesting preclinical signals and no human data at all.